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Postpartum vitamin A supplementation of mothers and infants is recommended, but the efficacy has been questioned. In this double-blind, placebo-
controlled trial, Kenyan mother–infant pairs were randomised to maternal vitamin A (400 000 IU) or placebo ,24 h postpartum, and infant vit-
amin A (100 000 IU) or placebo at 14 weeks. Milk retinol was determined at weeks 4, 14 and 26, and maternal and infant serum retinol at weeks 14
and 26. Infant retinol stores were assessed at week 26, using a modified relative dose response (MRDR) test. Among 564 women, serum retinol at
36 weeks gestation was 0·81 (SD 0·21) mmol/l, and 33·3% were ,0·7mmol/l. Maternal serum retinol was not different between groups, but milk
retinol was higher in the vitamin A group: (0·67 v. 0·60mmol/l; 0·52 v. 0·44mmol/l; 0·50 v. 0·44mmol/l at 4, 14 and 26 weeks, respectively). When
expressed per gram fat, milk retinol was higher in the vitamin A group only at 4 weeks. Infant serum retinol was not different between groups.
However, although most infants had deficient vitamin A stores (MRDR . 0·06%) at 26 weeks, vitamin A to infants, but not mothers, resulted in a
lower proportion of infants with deficient vitamin A stores (69 v. 78%). High-dose postpartum vitamin A supplementation failed to increase serum
retinol and infant stores, despite modest effects on milk retinol. Infant supplementation, however, increased stores. There is a need for a better
understanding of factors affecting absorption and metabolism of vitamin A.
Vitamin A: Supplementation: Postpartum: Breast milk: Kenya
Vitamin A deficiency is widespread among women of repro-
ductive age and children in low-income countries (Humphrey
et al. 1992; West, 2002), and regular high-dose vitamin A sup-
plementation has been shown to reduce mortality among chil-
dren from 6 months to 5 years (Fawzi et al. 1993). Assuming
similar survival benefits for young infants, the research
priority has shifted towards development of interventions to
improve vitamin A status in the first 6–9 months of life.
Maternal vitamin A supplementation during the immediate
postpartum period is a potentially effective strategy for simul-
taneously improving the vitamin A status of the women and
their breast-fed infants (Stoltzfus et al. 1993; World Health
Organization, 1998). However, studies have suggested that
the recommended vitamin A dose of 200 000 IU is inadequate
(Rice et al. 1999), even in combination with 25 000 IU given
to infants at 6, 10 and 14 weeks (World Health Organiz-
ation/CHD, 1998). It has therefore been suggested that the
recommendation should be changed to 400 000 IU vitamin
A given as two doses (Ross, 2002).
The present study set out to assess the effects of high-dose
postpartum maternal supplementation with 400 000 IU and
infant supplementation with 100 000 IU at 14 weeks of age,
on maternal and infant vitamin A status in the 6-month post-
partum period.
Subjects and methods
Study design
The study was a randomised, placebo-controlled, double-
blind, two-by-two factorial trial, conducted between July
1999 and November 2001. The mothers were randomly allo-
cated 400 000 IU vitamin A (A) or placebo (P) within 24 h
of delivery, and their infants were randomly allocated
100 000 IU vitamin A (a) or placebo (p) at 14 weeks of age,
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when the diphtheria–pertussis–tetanus and oral polio vaccines
were given. Thus, there were four combinations of the two
placebo-controlled interventions: maternal and infant vitamin
A supplement (Aa), maternal vitamin A and infant placebo
supplement (Ap), maternal placebo and an infant vitamin A
supplement (Pa), and placebo to both mother and infant
(Pp). The effects of the maternal intervention were assessed
through determination of maternal serum retinol at weeks 14
and 26 postpartum, and breast milk retinol at weeks 4, 14
and 26. The effects of both interventions were assessed by
infant vitamin A status determined by serum retinol at
weeks 14 and 26 week and the modified relative dose response
test (MRDR) at week 26.
Study area and population
The study was conducted in Bondo District, rural western
Kenya, at the shores of Lake Victoria approximately 1200m
above sea level. The population practise subsistence farming
and fishing. The main crops grown are maize, finger millet,
cassava, sorghum, pulses and sweet potatoes. Vitamin A-rich
foods, predominantly from plant sources, such as mangoes,
papaya and dark green leafy vegetables are readily available
but not widely consumed. The prevalence of HIV infection
among antenatal attendees was above 28% at the time of
the study (National AIDS Control Programme, 2001).
After informed consent, all women less than 24 weeks preg-
nant attending antenatal health care were invited to participate
in the study. Gestational age was assessed by ultrasonography.
A baseline interview about obstetric history and socio-demogra-
phy was conducted, and anthropometric data were collected. A
blood sample was collected and kept in a cool box at 4–88C
during transport to the laboratory for later serum retinol anal-
ysis. At 36 weeks gestation, another blood sample was drawn
for analysis of serum retinol, which was considered the baseline.
We assumed that the standard deviations of maternal and
infant serum retinol at 3 months and of infant serum retinol
at 6 months postpartum were not greater than 0·5mmol/l
(Stoltzfus et al. 1993). We therefore needed to recruit 250
women in each group to detect a 0·17mmol/l difference with
90% power and 95% confidence, while allowing for a 20%
loss to follow-up. Assuming an interaction between maternal
and infant supplementation, we would be able to detect a
0·23mmol/l difference in infant serum retinol at 26 weeks of
age between the four subgroups of infants.
Randomisation and intervention
Enrolment into the trial and randomisation only took place
after delivery of a live singleton baby. Hoffmann La Roche
Ltd (Basel, Switzerland) prepared and supplied the vitamin
A and identical-looking placebo supplements as oily capsules
in brown bottles coded as X or Y. To avoid mistakes between
maternal and infant doses, maternal capsules (two capsules
containing 200 000 IU dose or placebo) were bright red,
while infant capsules (one containing 100 000 IU dose or pla-
cebo) were blue. Two random sequences of X and Y were pre-
pared, one for the mothers and one for the infants.
Identification numbers from 1 to 700 were assigned consecu-
tively to each of the two lists and mother–infant pairs of cap-
sules were packaged in zip-lock bags numbered from 1 to 700
and kept (48C) in batches of ten. The randomisation codes
were concealed for the entire trial duration and only revealed
after completion of data analysis.
As part of the national antenatal case guidelines all pregnant
women received presumptive malarial treatment in their
second and third trimesters. Further, iron and folic acid were
given according to national guidelines. All the infants received
100 000 IU vitamin A after the trial, at 8 months of age. The
trial was conducted prior to the availability of HIV testing
and antiretroviral prophylaxis for antenatal women in public-
sector facilities in western Kenya.
Examinations, storage and analysis of biological specimens
The data collected at week 36 during gestation served as the
baseline. Study outcomes were assessed at weeks 4, 14 and
26 postpartum. Maternal height was measured without shoes
to the nearest 0·1 cm using a portable height measure (Leice-
ster portable height measure; CMS, London, UK). Maternal
body weight was measured in light clothing to the nearest
100 g using an electronic scale (UNISCALE; UNICEF,
Copenhagen, Denmark).
All biological specimens were stored at 21968C for 3
months, before transfer to the laboratory in Nairobi where
they were stored at 2208C for a maximum of 9 months
before analysis. Serum concentrations of retinol were
measured in non-fasting venous blood using HPLC (Hitachi
Ltd, Tokyo, Japan) with retinyl acetate as internal standard,
and hexane as the extracting solvent. The retinol standard
curve was prepared from known concentrations of retinol
against peak area ratio of retinol/retinyl acetate with detection
wavelength at 325 nm. Serum retinol concentration
,0·7mmol/l was used to define low vitamin A status in
both mothers and infants (World Health Organization, 1996).
For the MRDR analysis conducted in infants at 26 weeks,
5ml venous blood were drawn 4 h after oral ingestion of
5·3mmol 3,4-didehydroretinol administered directly into the
infants mouth (Tanumihardjo et al. 1996). The infant was
breast-fed on demand during the 4 h waiting period. Serum
was extracted and analysed as normal serum samples with
the only exception that the wavelength used to detect retinol,
retinyl acetate (internal standard) and 3,4-didehydroretinol
was 350 nm. Standard curves were prepared for both 3,4-dide-
hydroretinol and retinol using known concentrations against
peak area ratio to internal standard (retinyl acetate).
A sample of 2–5ml foremilk was obtained from each
mother by manual expression, after at least 1 h without nurs-
ing. The milk samples were kept cool until determination of
milk fat within 4 h of collection and before freezing. Milk
fat was determined by the creamatocrit method (Lucas et al.
1978) before storage. After thawing, to release retinol from
fatty acids in milk, the samples were saponified before extrac-
tion with 3,4-didehydroretinol serving as the internal standard.
After saponification with potassium hydroxide (KOH–H2O,
60:40, w/v) at 608C for 30min the sample was cooled and
extracted twice with hexane. After evaporation, the residue
was reconstituted with mobile phase and injected into the
HPLC system. The retinol standard curve was prepared
using known concentrations of retinol against retinol/3,4-di-
dehydroretinol peak area ratio when detected at 325 nm. The
retinol content in milk per volume (mmol/l) and per gram of
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milk fat (mmol/g) were calculated. According to WHO
criteria, values #1·05mmol/l and #0·28mmol/g fat were con-
sidered low (World Health Organization, 1996).
Serum concentrations of the acute-phase protein a1-antichy-
motrypsin (ACT) and of ferritin were measured by automated
turbidity (Cobas Mira Plus; Roche, Basel, Switzerland).
Rabbit antihuman ACT (DAKO, Glostrup, Denmark) was
used to precipitate ACT and turbidity was measured at 345 nm
after incubation for 8·3min at 378C. The results were given as
g/l serum on the basis of a standard curve from commercial cali-
brators (DAKO). Serum ferritin wasmeasured by a fluoroimmu-
noassay kit (DELFIA Ferritin; Wallac, Turku, Finland) with the
detection based on a europium-labelled monoclonal antibody
against human ferritin. The detection limit was 0·5mg/l. The
accuracy was confirmed by participation in a national control
program (Danish Institute for External Quality Assurance
(DEKS), Denmark).
Statistical analyses
Data were checked for reasonably normal distribution using
cumulative normal plots. t test and x2 test were used to test
for differences in means and proportions, respectively. Differ-
ences between baseline and week 14 or 26 postpartum were
tested for each treatment group using paired t tests. Pearson’s
x2 test was used to test for differences in proportions between
the two groups, or when numbers were small with Fisher’s
exact test.
In linear regression, the serum retinol deficits associated
with elevated serum ACT between 0·3–0·35, 0·35–0·4, 0·4–
0·5, 0·5–0·6 and above 0·6 g/l were estimated, and baseline
serum retinol then adjusted accordingly. The effects of
supplementation on maternal and infant serum retinol were
controlled for adjusted baseline maternal serum retinol, as
well as for elevated serum ACT, using dummy variables, at
the time the end-point sample was taken.
All analyses were by intention-to-treat. The level of signifi-
cance used was 0·05.
Ethical permissions
Ethical permissions to conduct the present study were
obtained from the ethics committees of the Kenya Medical
Research Institute, the London School of Hygiene and Tropical
Medicine and the Danish Central Medical Ethics Committee.
Results
During pregnancy 651 women were identified as eligible and
recruited into the study. At the time of delivery, 584 were still
living in the study area, were willing to participate in the trial
and had delivered live singleton babies. Eventually, 564 were
enrolled into the trial and randomised to receive vitamin A or
placebo after delivery (Fig. 1). Among the 564 eventually ran-
domised, the mean maternal age at recruitment between 14
and 24 weeks of gestation was 24·7 years (range 14–48
years), and 19·6% were primigravidae. Mean serum retinol
was 0·96 (SD 0·27) mmol/l at recruitment, and 0·81 (SD 0·21)
mmol/l at week 36 of gestation. Mean birth weight was 3·11
(SD 0·47) kg, and 52% of the newborns were male.
Randomisation resulted in similar distribution of maternal
and infant baseline characteristics in mother–infant pairs
Fig. 1. Trial profile.
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allocated to maternal vitamin A supplementation or placebo
(A or P), and to the four combinations of maternal and
infant supplementation (Aa, Ap, Pa or Pp) (Table 1).
There were no differences with respect to symptoms after
24 and 48 h between those allocated to placebo and vitamin
A, neither among women or infants. Bulging fontanels was
seen in four (1·8%) infants receiving placebo and in eight
(3·6%) receiving vitamin A (P¼0·26). During the first 6
months, forty-six infants died. There were no differences by
maternal or infant vitamin A supplementation: twenty-three
had been randomised to maternal vitamin A and twenty-
three to maternal placebo supplementation (P¼1·00). Simi-
larly, twenty-two had been randomised to infant vitamin A
and twenty-four to infant placebo supplementation (P¼0·70).
Maternal serum and breast milk retinol 14 weeks postpar-
tum were determined in 71% (402) and 75% (422) of the
564 women, respectively, and infant MRDR at 26 weeks of
age were determined in 64% (361) infants. There were no sig-
nificant differences in maternal age, BMI, serum retinol at
recruitment and 36 weeks of gestation, and birth weight, and
proportion primigravidae, married or infant sex between
mother–infant pairs lost to follow-up or those followed up
for serum retinol at 14 weeks postpartum. However, those
lost to follow-up for determination of breast milk retinol at
14 weeks and MRDR at 26 weeks had significantly lower
birth weights than those followed up for these outcomes.
Effects on maternal serum retinol
The mean increments in maternal serum retinol from week 36
of gestation to 14 and 26 weeks postpartum were 0·22 (95% CI
0·18, 0·26) and 0·14 (95% CI 0·10, 0·18) mmol/l, respectively.
The effect of maternal vitamin A supplementation was
expressed as the difference (vitamin A 2 placebo) in increase
in serum retinol from week 36 of gestation to 14 and 26 weeks
postpartum. There were no effects of maternal vitamin A sup-
plementation on increase in maternal serum retinol, neither at
14 (0·05mmol/l; 95% CI 20·03, 0·12) nor 26 (20·02mmol/l;
95% CI 20·10, 0·06) weeks postpartum (Table 2). The
estimates did not change after controlling for adjusted baseline
serum retinol, and elevated serum ACT at follow-up (data not
shown).
To assess if the effect of maternal vitamin A supplementation
depended on levels of background characteristics (serum retinol,
ferritin and ACT, gravidity, birth weight, sex), tests for inter-
actions were done using multiple linear regression analysis.
The effects of 0·11mmol/l (95% CI 20·005, 0·22, P¼0·06)
among those with serum retinol below 0·70mmol/l at week 36
of gestation, and 0·01mmol/l (95% CI 20·08, 0·10, P¼0·83)
among those with serum retinol at or above 0·7mmol/l did not
differ significantly (interaction, P¼0·20).
The effect of maternal vitamin A supplementation depended
on serum ferritin at week 36 of gestation (interaction,
P¼0·025), due to a greater effect in those with serum ferritin
above 12mg/l (0·13; 95% CI 0·02, 0·25, P¼0·02) compared
to those below (20·04; 95% CI 20·14, 0·06, P¼0·47).
The effect of maternal vitamin A supplementation was
0·11mmol/l (95% CI 20·002, 0·21, P¼0·055) among mothers
to infants with birth weight below 3000 g, and 20·03 (95% CI
20·14, 0·07, P¼0·55) among mothers to infants with birth
weight above 3000 g, but this difference was not significant
(interaction, P¼0·09). There were no interactions between
maternal supplementation and gravidity, serum ACT and
infant sex.
Table 1. Baseline maternal and infant characteristics by maternal and infant supplementation group
Maternal supplementation
Vitamin A (A) (n 282) Placebo (P) (n 282)
Infant, vitamin A (a)
(n 142)
Infant, placebo (p)
(n 140)
Infant, vitamin (a)
(n 143)
Infant, placebo (p)
(n 139)
Mean SD Mean SD Mean SD Mean SD
Maternal
Weeks 16–24 of gestation
Maternal age (years) 24·3 6·5 25·5 7·2 24·6 6·2 24·4 6·4
Married (%) 80·7 83·6 86·6 80·4
Gravidity* 2 1–4 2 1–4 2 1–4 2 1–4
Weight (kg) 58·0 7·3 57·8 7·5 58·8 8·0 58·2 7·5
Height (cm) 162·4 5·9 161·7 5·9 161·9 6·4 162,4 5·8
BMI (kg/m2) 22·0 2·2 22·1 2·5 22·4 2·4 22·1 2·4
Serum retinol (mmol/l)† 0·91 0·25 0·97 0·27 0·97 0·26 0·96 0·28
Week 36 of gestation
Serum retinol (mmol/l)† 0·79 0·20 0·81 0·21 0·82 0·18 0·84 2·6
Serum ACT (g/l)*‡ 0·32 0·28–0·38 0·31 0·28–0·37 0·31 0·28–0·37 0·32 0·27–0·38
Serum ferritin (mg/l)*‡ 9·8 6·7–19·9 10·4 6·9–20·4 12·3 6·5–25·4 10·4 6·5–21·8
Infant
Birth weight (kg) 3·10 0·50 3·14 0·46 3·13 0·44 3·08 0·48
Male sex (%) 57·0 46·9 47·6 56·5
ACT, a1-antichymotrypsin.
* Median and interquartile range.
† Data available for 121 (A/a), 120 (A/p), 130 (P/a), 119 (P/p) at week 16–24, and 94 (A/a), 99 (A/p), 97 (P/a), 83 (P/p) at week 36.
‡ Data available for 126 (A/a), 128 (A/p), 118 (P/a), 110 (P/p).
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Effects on breast milk retinol
Mean breast milk retinol was 0·64mmol/l (95% CI 0·61, 0·67)
at 4 weeks, and then declined to 0·48mmol/l (95% CI 0·46,
0·51) and 0·47mmol/l (95% CI 0·45, 0·50) at 14 and 26
weeks postpartum, respectively. The proportions with values
below 1·05mmol/l were 88·7% at 4 weeks, and above 96%
at 14 and 26 weeks. All women had milk retinol per gram
fat below the cut-off of 0·28mmol/g at all time-points. Never-
theless, vitamin A supplementation was associated with sig-
nificantly higher milk retinol per volume at 4, 14 and 26
weeks postpartum, and higher milk retinol expressed per
gram fat at week 4, but not at weeks 14 and 26 (Table 3).
There were no interactions with gravidity, maternal baseline
serum retinol and ferritin, birth weight and infant sex, and
the estimates did not change after controlling for adjusted
baseline serum retinol, and elevated serum ACT at 14 and
26 weeks follow-up (data not shown).
Infant serum retinol and modified relative dose response
Mean serum retinol was 0·92mmol/l (95% CI 0·89, 0·94)
among 317 infants examined at 14 weeks, and 1·04mmol/l
(95% CI 1·01, 1·07) among 280 infants examined at 26
weeks of age. At 14 weeks, there was no significant difference
in infant serum retinol between those of mothers allocated to
placebo and vitamin A. At 26 weeks, there were no differ-
ences in infant serum retinol between infants of mothers allo-
cated to placebo and vitamin A, or between infants receiving
placebo or vitamin A (interaction, P¼0·09). The estimates did
not change after controlling for adjusted maternal baseline
serum retinol, and elevated infant serum ACT at follow-up
(data not shown).
MRDR ratio, a measure of vitamin A stores, was deter-
mined among 361 infants at 26 weeks of age. The mean
MRDR ratio was 0·081 (95% CI 0·077, 0·084), with 74·5%
having values above 0·06 used to define low vitamin A
Table 2. Maternal serum retinol concentration at week 36 of gestation, and at weeks 14 and 26 postpartum
Vitamin A Placebo
Difference
(vitamin A2 placebo)
Mean 95 % CI Mean 95 % CI Mean 95 % CI P
Week 36 of gestation n 193 n 180
Serum retinol (mmol/l) 0·80 0·83 – –
,0·7 (%)* 36·8 27·2 – –
Week 14 postpartum n 205 n 197
Serum retinol (mmol/l) 1·05 1·02, 1·08 1·01 0·97, 1·05 0·04 20·01, 0·09 0·13
, 0·7 (%)* 8·7 5·3, 13·5 13·7 9·2, 19·3 24·9 211·1, 0·01 0·12
Week 26 postpartum n 148 n 143
Serum retinol (mmol/l) 0·96 0·91, 1·00 0·98 0·93, 1·02 20·02 20·08, 0·04 0·50
, 0·7 (%)* 11·5 6·8, 17·8 14·0 8·8, 20·8 22·5 210·2, 5·2 0·52
Increase from 36 weeks
To week 14 n 134 n 122
Serum retinol (mmol/l) 0·24 0·19, 0·30 0·20 0·15, 0·25 0·05 20·03, 0·12 0·21
To week 26 n 91 n 82
Serum retinol (mmol/l) 0·13 0·07, 0·19 0·15 0·10, 0·20 20·02 20·10, 0·06 0·58
* Proportion.
Table 3. Milk retinol and fat concentrations at 4, 14 and 26 weeks postpartum
Vitamin A Placebo
Difference
(vitamin A 2 placebo)
Mean 95 % CI Mean 95 % CI Mean 95 % CI P
Week 4 postpartum n 215 n 199
Milk retinol (mmol/l) 0·67 0·63, 0·72 0·60 0·56, 0·65 0·07 0·004, 0·14 0·04
,1·05 (%)* 85·6 80·2, 90·0 92·0 87·3, 95·3 26·4 212·5, 20·2 0·03
Milk fat (g/l) 34·6 31·9, 37·2 37·3 34·5, 40·0 22·7 26·5, 1·1 0·16
Milk retinol/fat (mmol/g)† 0·025 0·022, 0·028 0·019 0·016, 0·023 0·006 0·001, 0·01 0·02
Week 14 postpartum n 221 n 201
Milk retinol (mmol/l) 0·52 0·49, 0·55 0·44 0·40, 0·47 0·08 0·03, 0·13 0·001
Milk fat (g/l) 31·5 29·0, 34·1 29·8 27·4, 32·2 1·7 21·8, 5·3 0·33
Milk retinol/fat (mmol/g)† 0·020 0·018, 0·021 0·019 0·017, 0·021 0·001 20·002, 0·004 0·43
Week 26 postpartum n 184 n 170
Milk retinol (mmol/l) 0·50 0·46, 0·53 0·44 0·41, 0·48 0·05 0·003, 0·10 0·04
Milk fat (g/l) 31·3 28·8, 33·8 30·1 27·4, 32·9 1·1 22·6, 4·9 0·54
Milk retinol/fat (mmol/g)† 0·020 0·018, 0·022 0·019 0·017, 0·021 0·001 20·001, 0·004 0·31
* Proportion.
† Due to missing creamatocrit data, n values in placebo and vitamin A groups were lower at week 4 (136 and 165), 14 (168 and 181) and 26 (142 and 152).
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Table 4. Infant serum retinol at 14 and 26 weeks of age, and modified relative dose response (MRDR) ratio according to maternal and infant treatment group
Intervention group (maternal/infant)* Difference† Difference†
A/a (n 142) A/p (n 140) P/a (n 143) P/p (n 139) Infant (a – p) Maternal (A – P)
Mean 95 % CI Mean 95 % CI Mean 95 % CI Mean 95 % CI Mean 95 % CI P Mean 95 % CI P
14 weeks
Serum retinol
(mmol/l)‡
0·90 0·85, 0·95 0·92 0·87, 0·96 0·95 0·89, 1·01 0·90 0·86, 0·93 – – 20·02 20·06, 0·03 0·51
, 0·7 (%)‡ 19·5 0·1, 38·9 16·7 23·6, 37·0 15·5 25·9, 36·9 14·0 25·6, 33·6 – – 3·5 216·6, 23·6 0·45
26 weeks
Serum retinol
(mmol/l)§
1·02 0·97, 1·07 1·08 1·00, 1·15 1·06 0·99, 1·13 1·02 0·97, 1·06 20·01 20·07, 0·05 0·77 0·01 20·05, 0·07 0·72
, 0·7 (%)§ 4·1 218·3, 26·5 8·0 213·7, 29·7 6·1 217·3, 29·5 6·1 217·3, 29·5 22·1 224·8, 20·6 0·62 0·02 25·6, 5·7 1·00
MRDR ratiok 0·076 0·069, 0·082 0·082 0·075, 0·088 0·073 0·067, 0·079 0·091 0·082, 0·100 20·012 20·019, 20·005 0·001 20·003 20·010, 0·004 0·39
$ 0·06 (%)k 70·4 52·8, 89·8 80·2 62·3, 98·1 68·5 52·6, 86·6 76·3 58·6, 94·0 28·9 219·5, 1·7 0·056 3·3 27·2, 13·8 0·55
$ 0·12 (%)k 11·3 0·8, 21·8 10·4 0·7, 20·0 8·7 21·3, 18·7 22·6 13·5, 31·7 26·5 225·8, 12·8 0·09 24·9 224·1, 14·3 0·21
Increase 14–26 weeks
Serum retinol
(mmol/l){
0·08 0·01, 0·16 0·13 0·05, 0·22 0·13 0·03, 0·24 0·10 0·04, 0·16 20·009 20·087, 0·068 0·81 20·01 20·08, 0·07 0·88
, 0·7 (%){ 215·4 28·7 29·4 27·9 24·5 0·86 23·5 0·58
* P is placebo and A is vitamin A; uppercase letter denotes maternal and lowercase letter denotes infant supplementation.
† Difference between infants receiving vitamin A minus placebo (a 2 p) and infants whose mothers received vitamin A minus placebo (A 2 P).
‡ Mean serum retinol and proportion with low values at 14 weeks. Data available for 86 (P/p), 78 (A/p), 71 (P/a), 82 (A/a).
§ Mean serum retinol and proportion with low values at 26 weeks. Data available for 66 (P/p), 75 (A/p), 66 (P/a), 73 (A/a).
kMean MRDR and proportion with high values at 26 weeks. Data available for 93 (P/p), 96 (A/p), 92 (P/a), 80 (A/a).
{Mean change in serum retinol and proportion with low values from 14–26 weeks. Data available for 55 (P/p), 46 (A/p), 40 (P/a), 49 (A/a).
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store. There was no interaction between maternal and infant
supplementation (P¼0·11), and only the main effects of
maternal and infant supplementation are therefore presented.
As seen from Table 4, maternal vitamin A supplementation
had no effect. In contrast, infant vitamin A supplementation
reduced MRDR ratios (20·012; 95% CI 20·019, 20·005),
and the proportion with high ratios (28·9%; 95% CI
219·5, 1·7). Infant supplementation was associated with
reduced risk of MRDR ratios above 0·06 (OR 0·66; 95% CI
0·41, 1·05, P¼0·08) and 0·12 (OR 0·56; 95% CI 0·30, 1·05,
P¼0·07). There was no confounding or interaction with
gravidity, maternal serum retinol, ferritin and ACT, birth
weight or sex.
Discussion
A maternal postpartum vitamin A dose of 400 000 IU (Ross,
2002), given at once, failed to increase maternal serum retinol,
but slightly increased breast milk retinol concentrations. The
effect on breast milk retinol was not followed by effects on
infant status. Nevertheless, supplementing the infants with
100 000 IU at 14 weeks increased vitamin A stores, as
measured by the MRDR test, but had no effects on infant
serum retinol.
Maternal supplementation
The modest effects on milk retinol and lack of effects on
maternal serum retinol and infant stores are in contrast to
those from trials among Indonesian and Bangladeshi women.
In Indonesia (Stoltzfus et al. 1993), a single dose of
300 000 IU given 1–3 weeks postpartum was shown to increase
maternal serum and milk retinol, and infant stores for up to 6
months. In Bangladesh (Rice et al. 1999), a single postpartum
dose of 200 000 IU vitamin A had no effects on maternal
serum retinol, but had beneficial effects on maternal MRDR
and milk retinol, which were followed by effects on infant
serum retinol and MRDR at 6 months of age. As part of the
Zimbabwe Vitamin A for Mothers and Babies trial to assess
the effects of immediate postpartummother–infant supplemen-
tation on infant mortality, 400 000 IU vitamin A given to the
mother within 96 h postpartum seemed to increase serum retinol
among HIV-uninfected mothers (Malaba et al. 2005).
In the present study, the lack of effect on maternal serum
retinol is not likely explained by the limitations of serum reti-
nol as a measure of vitamin A status. Serum retinol is home-
ostatically controlled across a wide range of liver stores
(Olson, 1984), and declines in the presence of an acute-
phase response (Thurnham & Singkamani, 1991). Neverthe-
less, the women in the present study had relatively low
serum retinol levels that should be sensitive to changes in
intake and status. Furthermore, we adjusted for elevated serum
ACT in our analyses, to account for the effect of the acute-
phase response on serum retinol. The maternal supplement
was followed by an increase in milk retinol, but only at 4
weeks postpartum when expressed relative to fat. Given the
modest effects on milk retinol, it is not surprising that no
effects were found on infant serum retinol and MRDR.
Alternatively, there could have been differences between
the trials, with respect to factors impairing absorption and
metabolisation of vitamin A. For example, inadequate intake
of fat in the diet may have impaired absorption, and co-exist-
ing deficiency of zinc intake may have impaired synthesis of
retinol binding protein and thus the mobilisation of vitamin
A from the liver (Lonnerdal, 1998). Furthermore, the present
data suggest that maternal iron status modified the effect of
vitamin A supplementation on maternal serum retinol, in
that the effect was significantly higher in women with non-
depleted iron stores.
Another notable difference between the trials is that we sup-
plemented the women within 24 h of delivery, whereas in the
trials from Indonesia and Bangladesh, the supplements were
administered between 1 and 3 weeks postpartum. Even
uncomplicated parturition is precipitating a substantial acute-
phase response, which peaks within the first week postpartum
(H Friis, unpublished results). If an acute-phase response is
impairing the absorption and metabolism of vitamin A, then
larger effects may be expected if the supplement is given
when the acute-phase response is fading, such as towards
the end of the 6-week infertile postpartum period within
which it is now recommended to give vitamin A.
A major limitation of the present study is the lack of data on
HIV status, despite an estimated prevalence above 28%.
While HIV infection is not likely to confound the present
results, it is likely that HIV infection impairs absorption and
increases requirements, and thus reduces the effect of vitamin
A supplementation on measures of status. This was found in
the Zimbabwe Vitamin A for Mothers and Babies trial,
where serum retinol increased among HIV-uninfected, but
not among HIV-infected women, after postpartum vitamin A
supplementation (Zvandasara et al. 2006). Of greater concern,
however, is if vitamin A supplementation when given to HIV-
infected mothers has effects on breastfeeding-associated
mother-to-child transmission and on mortality among HIV-
infected children. Daily ante- and postnatal maternal
supplementation with vitamin A given as preformed vitamin
A and provitamin A carotenoids may increase mother-to-
child HIV transmission (Fawzi et al. 2002), although this
was not found in trials with similar interventions (Coutsoudis
et al. 1999; Kumwenda et al. 2002). Also, recent data
from the Zimbabwe Vitamin A for Mothers and Babies
trial found no effects of maternal postpartum vitamin A
supplementation on mother-to-child HIV transmission
(Humphrey et al. 2006).
Infant supplementation
Infant supplement containing 100 000 IU vitamin A given at
14 weeks was neither associated with bulging fontanels and
other acute signs, nor with mortality up to 6 months. Infant
supplementation had no effect on serum retinol at 26 weeks,
but increased the infant vitamin A stores, as assessed by the
MRDR. This effect was in accord with the World Health
Organization/CHD multi-country trial (1998), which found
that a maternal postpartum supplement of 200 000 IU com-
bined with infant supplement of 25 000 IU at 6, 10 and 14
weeks reduced the proportion of infants with low serum reti-
nol at 6 months.
While the benefit of regular high-dose vitamin A sup-
plementation of older infants and young children (6 months
to 5 years) on mortality is well established, data on the
effect of vitamin A supplementation among young infants
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(,6 months) are inconsistent. Among infants of HIV-negative
mothers, neonatal vitamin A supplementation (50 000 IU as
one or two doses) reduced mortality among Indonesian and
Indian (Humphrey et al. 1996; Rahmathullah et al. 2003),
but not among Zimbabwean infants (Malaba et al. 2005). In
a study among young Indonesian infants, there were no overall
effects on mortality of 50 000 IU (,1month) or 100 000 IU
(1–5 months) (West et al. 1995). Similarly, no effects of
25 000 IU given after 6, 10 and 14 weeks on mortality were
found in the World Health Organization/CHD study (1998).
The Zimbabwe Vitamin A for Mothers and Babies trial
found that among infants of HIV-positive mothers, the effect
of neonatal vitamin A supplementation depended on the
timing of infant HIV infection (Humphrey et al. 2006):
there were no effects in infants found positive at birth,
whereas mortality was reduced in those found negative at
birth and positive at 6 weeks, and increased in those found
negative at 6 weeks.
Conclusion
The aim of the present trial was to contribute to the devel-
opment of feasible interventions to increase vitamin A
status among young infants. The inadequate effect of increas-
ing doses, and combining maternal and infant doses, and
the inconsistent results from different trials, suggest that
other factors may modify the absorption and metabolisation
of vitamin A.
Furthermore, this and similar trials were based on the
assumption that improved vitamin A status would reduce
infant morbidity and mortality, similar to what has been
shown among children between 6 months and 5 years. Emer-
ging data, however, suggest that the effects of vitamin A inter-
ventions are not fully explained by their effect on status. The
effects of a specific vitamin A intervention, both in terms of
vitamin A status and morbidity and mortality, may be
modified by co-existing nutritional deficiencies, the infectious
disease pattern, recent immunisations and other factors.
Recommendations should therefore be based on evidence
for beneficial effects on morbidity and mortality, rather than
on status.
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